Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat). - Wikidata - wikimedia - TriplyDB

Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat).

Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat).

http://www.wikidata.org/entity/Q35016969

about

To Extinguish the Fire from Outside the Cell or to Shutdown the Gas Valve Inside? Novel Trends in Anti-Inflammatory Therapies Manipulation of the host protein acetylation network by human immunodeficiency virus type 1 The macrophage: a therapeutic target in HIV-1 infection HDAC inhibitors and immunotherapy; a double edged sword?Histone deacetylases as targets for treatment of multiple diseases Concise Review: Epigenetic Regulation of Myogenesis in Health and Disease Histone deacetylase 3 (HDAC 3) as emerging drug target in NF-κB-mediated inflammation Controlling the HIV/AIDS epidemic: current status and global challenges Prospects for treatment of latent HIV.Lysine deacetylase inhibition prevents diabetes by chromatin-independent immunoregulation and β-cell protection Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer.Histone deacetylase inhibitor suppresses virus-induced proinflammatory responses and type 1 diabetes.Specific inhibition of histone deacetylase 8 reduces gene expression and production of proinflammatory cytokines in vitro and in vivo Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer Effects of the histone deacetylase inhibitor ITF2357 in autoinflammatory syndromes.Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir.HDAC inhibition and graft versus host disease Autophagy induction by histone deacetylase inhibitors inhibits HIV type 1.Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.Emerging treatments for essential thrombocythemia Givinostat inhibition of hepatic stellate cell proliferation and protein acetylation.Implication of the intestinal microbiome as a potential surrogate marker of immune responsiveness to experimental therapies in autoimmune diabetes.Targeting epigenetic regulations in cancer In Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors.ITF2357 transactivates Id3 and regulate TGFβ/BMP7 signaling pathways to attenuate corneal fibrosis.Preclinical studies in the mdx mouse model of duchenne muscular dystrophy with the histone deacetylase inhibitor givinostat Class I and II histone deacetylase inhibition by ITF2357 reduces SLE pathogenesis in vivo.HDAC inhibition in rheumatoid arthritis and juvenile idiopathic arthritis.Inhibition of histone deacetylases in inflammatory bowel diseases.Toxicological and metabolic considerations for histone deacetylase inhibitors.Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials.Targeting of histone deacetylases in brain tumors.Histone deacetylase inhibitors: a potential epigenetic treatment for Duchenne muscular dystrophy.Givinostat, a type II histone deacetylase inhibitor, induces potent caspase-dependent apoptosis in human lymphoblastic leukemia.Hybrids from Farnesylthiosalicylic Acid and Hydroxamic Acid as Dual Ras-Related Signaling and Histone Deacetylase (HDAC) Inhibitors: Design, Synthesis and Biological Evaluation.Epigenetic drug discovery: breaking through the immune barrier.Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation.Host modulation therapy with anti-inflammatory agents.Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits Ex Vivo Lipopolysaccharide-Induced Inflammatory Responses.Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer.

P2860

Q26786973-8B3BCAE5-FAC0-4A65-92C7-74A4925AB915 Q26795463-BE6A86F0-5719-4DD9-80B8-7F2B87445E13 Q26823236-1A59381D-A1A9-4EFE-97FA-FF4F8CCDBA68 Q26853102-06968452-F485-494D-918F-99A3FF3799D9 Q27000389-03FAB4E3-49A1-4928-83D2-138BABA6BADC Q28072184-6054159B-855C-4AEF-91AA-E2E0BB0799E3 Q28076052-9F8EB431-B26D-48CD-9691-C9610692FBFB Q30420558-56B87616-842E-4D40-8157-4B7ACDC60D0E Q30424413-31985640-D170-4746-ADC2-3C9A0A8FBE49 Q32945672-10DF9014-6162-462C-A50D-F9415F8D759B Q34346813-C4EC0B19-57D1-45DF-A2BA-2566810B541E Q34975260-5767EA33-A31F-4787-98C8-008BD4DD4F26 Q35002986-11BD4C82-185A-4C2C-9661-CEDC77997F7C Q35016934-28295387-F5E1-42E7-8D5F-AB9566F7584E Q35016951-1ECE5902-A59E-434F-905C-F4FD653D02E0 Q35016964-578B99FA-B316-492E-A2FD-7D2422E5E0DB Q35016985-2D19D353-1984-46ED-B7DD-3C03AFA9C3A3 Q35103991-1AD94F30-6B34-4542-BFCF-1B8859AFA17E Q35214924-885F44BD-D467-4F8B-A9D1-FB81CF251658 Q35683853-CAB9E4F8-5A80-466D-83E8-20E8300F63F0 Q35718150-56BCD29F-D5A8-477A-87FB-2148B02B9EDC Q36310672-F9C16D77-4200-4DA9-9BD1-202A14C19F5A Q36398751-38FB7A8E-67CF-429D-B201-803733620019 Q36523946-6A1D0C5C-F77A-4209-88B1-8CDDF9F34B7B Q36569602-3AF03383-8D14-4D0A-8E50-3EDD14CE0DA2 Q36885666-6C31B9F7-04E8-4DE7-9185-B98E3D5DE3F1 Q37657613-3D27115D-A9C8-4DE4-86F0-06DBDB0F0213 Q37838731-9873BA28-7E6D-4C49-B181-DB34202DD343 Q37848684-656ADEA0-3D2E-4A66-B7DD-76010A481EF6 Q38071321-3B6003FE-87E5-496F-9B4E-C65C946D0A5A Q38096822-F3B92FA9-D870-4F70-B7A2-ABDD35A1E27A Q38233117-65AC95AD-F592-4380-B00B-F580A500E780 Q38272315-68AD1CDB-51AE-4FFC-BF82-3A158F98598C Q38723094-889FEE91-C8B2-44A5-94A9-E507700B13CE Q38886102-5FC02F72-BCF1-4D42-8E76-15C5A7E7E298 Q38986705-64EBD7A5-B291-49E5-B0FE-0D7CE087BD96 Q41885967-2462BD86-FA06-411A-9E7B-ACF72BA1E4C1 Q48585276-F589F057-C2A0-4919-B12C-E4AB75709201 Q50281172-A2D55031-EA37-45F1-A035-8EC53CFBB61C Q50348505-72041C81-3F93-4C18-8BC6-7EA5E7B918F3

P2860

Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat).

http://www.wikidata.org/entity/Q35016969

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Pharmacokinetics, safety and i ...... nhibitor ITF2357 (givinostat).

@ast

Pharmacokinetics, safety and i ...... nhibitor ITF2357 (givinostat).

@en

type

label

Pharmacokinetics, safety and i ...... nhibitor ITF2357 (givinostat).

@ast

Pharmacokinetics, safety and i ...... nhibitor ITF2357 (givinostat).

@en

prefLabel

Pharmacokinetics, safety and i ...... nhibitor ITF2357 (givinostat).

@ast

Pharmacokinetics, safety and i ...... nhibitor ITF2357 (givinostat).

@en

P1433

Q35016969-0D4A7DB1-C222-410D-8573-4A87A5050CAE

P1476

Q35016969-D2546BFB-A62B-4882-9D41-3EE8FDE5B4FE

P2093

Q35016969-4BDCAEA5-6BF6-45B3-A7B6-F2AB60CE6661

Q35016969-632CADDA-7364-4F6F-996D-18763E8629CD

Q35016969-7916EE42-DE7E-414E-B6D5-CA4777BD6A81

Q35016969-C8AD9E6B-91A6-47C9-92B2-C33354C3D04E

Q35016969-D5FDF42F-211B-4BFA-80DC-3BB8E3F24C9D

Q35016969-EFBB59D6-B097-4622-A249-820E9C607C77

Q35016969-F057F2D2-ACED-4898-BC42-B50710892810

P2860

Q35016969-02995AF7-2B81-4F19-9242-2761B6DE2070

Q35016969-11FE8396-85B3-48C7-AEDB-C6EC6A2887A1

Q35016969-14A52D92-53F2-4139-883F-34B2B64F721A

Q35016969-2CF5C876-378F-4D3D-B15F-029EBDAF333C

Q35016969-39D1D541-DEE0-4351-AF46-FDF715524B3E

Q35016969-3A781127-71E4-4D59-B999-56FD8198EDAD

Q35016969-434F7698-C6F3-4F35-BD7B-EC0C1589BD68

Q35016969-478F8D82-F089-4264-86A5-B469772B5B8F

Q35016969-4E063FA7-712A-4132-B023-59BBEBB433D5

Q35016969-4F44EEA8-1AF0-4843-ACA0-735C36B6B023

P2888

Q35016969-F28FC5D0-DBF9-4890-803F-7891CDEF4E88

P304

Q35016969-F6A76DD3-624D-4F17-9290-11047333C0C3

P31

Q35016969-D6919CB0-0EBD-4891-B033-B4BC4343F103

P356

Q35016969-6549BEB0-0AF2-4F1C-8B12-996C3BC6D6E4

P407

Q35016969-52C5C7E0-547E-472D-8B67-CFA1345A3EF2

P433

Q35016969-0B0B9479-9DF9-4353-807D-591EEB183457

P478

Q35016969-E7B2F239-2159-461D-9002-68B1BB40488F

P50

Q35016969-9946071C-0DD6-4B04-9BD8-7244D95274A6

P577

Q35016969-0256EE65-90B9-481D-8749-339263949C49

P5875

Q35016969-008E83DE-A217-479F-9DE1-48CD8013D156

P6179

Q35016969-09032AD9-75F1-4FD7-AEBC-707987E2074E

P698

Q35016969-83193F81-A0FB-40CB-AB7B-AB399C38C561

P921

Q35016969-8F1ECB66-9E42-45A6-8BF9-65D3E49B9F7D

P932

Q35016969-1D2DA5B7-1B85-4C38-930F-6DF2C5469C28

P356

MOLMED.2011.00020

P1433

Molecular Medicine

P1476

Pharmacokinetics, safety and i ...... nhibitor ITF2357 (givinostat).

@en

P2093

Antonio Furlan

http://www.w3.org/2001/XMLSchema#string

Daniela Modena

http://www.w3.org/2001/XMLSchema#string

Flavio Leoni

http://www.w3.org/2001/XMLSchema#string

Gianluca Fossati

http://www.w3.org/2001/XMLSchema#string

Leonid L Reznikov

http://www.w3.org/2001/XMLSchema#string

Paolo Mascagni

http://www.w3.org/2001/XMLSchema#string

Valmen Monzani

http://www.w3.org/2001/XMLSchema#string

P2860

NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder

The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin.

Identification of a locus on chromosome 1q44 for familial cold urticaria.

Beneficial response to anakinra and thalidomide in Schnitzler's syndrome

Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells

Duration of nuclear NF-kappaB action regulated by reversible acetylation

Altered cytokine production in mice lacking P2X(7) receptors

Cooperation between complexes that regulate chromatin structure and transcription

Immunoglobulin D enhances the release of tumor necrosis factor-alpha, and interleukin-1 beta as well as interleukin-1 receptor antagonist from human mononuclear cells.

Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease.

P2888

molmed.2011.00020

P304

353-362

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2119/MOLMED.2011.00020

http://www.w3.org/2001/XMLSchema#string

P407

P433

5-6

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

Charles A. Dinarello

P577

2011-02-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50251038

http://www.w3.org/2001/XMLSchema#string

P6179

1068965357

http://www.w3.org/2001/XMLSchema#string

P698

21365126

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

3105139

http://www.w3.org/2001/XMLSchema#string